Similar studies for GEO DataSets (Select 200098920) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from GEO DataSets

Items: 5

Select item 2000989201.

Dual effect of the Nrf2 inhibitor for inhibition of HCV and cell proliferation

(Submitter supplied) We investigated whether brusatol, an Nrf2 inhibitor, has dual effects as anti-HCV and anti-hepatocellular carcinoma (HCC) and whether brusatol can enhance the similar dual effects of sorafenib. We showed that brusatol has dual effects as anti-HCV and anti-HCC and can enhance the similar in vitro effect by sorafenib and that there is potential of combination therapy of brusatol and sorafenib for HCV-related HCC.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL13915
2 Samples

Download data: TXT

Series

Accession:: GSE98920

ID:: 200098920

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000523212.

Control Huh7.5 cell vs HPI cell (HCV-persistently-infected Huh7.5 cell)

(Submitter supplied) Transcriptional profiling of human hepatoma cell lines comparing control uninfected Huh7.5 cells with Huh7.5 cells persistently infected with HCV (HPI cell). The latter maintains and produces HCV.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL5639
1 Sample

Download data: GPR

Series

Accession:: GSE52321

ID:: 200052321

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000604883.

Expression data from Tp80-Treated HCV replicon cell, Huh7/RepFeo.

(Submitter supplied) Tp80 is a novel antiviral compound. Antiviral mechanism of Tp80 is the inhibition of the viral genome replication through the recoverly of GPx2 expression downregulated by HCV infection. We used microarrays to evaluated the effect of Tp80 on the transcriptome of HCV replicon cells, compared with Non-infected host cells or non-treated HCV replicon cells.